Vigil Neuroscience

vigil neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. we are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. vgl101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (trem2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (alsp), a rare and fatal neurodegenerative disease. we are also developing vg-3927, a novel small molecule trem2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on alzheimer’s disease (ad) in genetically defined subpopulations.